Hunan Eneng Biopharmaceutical
Traditional Chinese Medicine (TCM) CXO and R&D services
About Hunan Eneng Biopharmaceutical
Hunan Eneng Biopharmaceutical Co., Ltd., also known as Yi Neng Pharmaceutical, is a contract research organization (CRO) focused on Traditional Chinese Medicine (TCM). Founded in December 2009 by Dr. Yi Yueneng, the company provides end-to-end services for the development of new TCM and natural drugs. Dr. Yi holds a master's degree in Pharmaceutics and a Ph.D. in Pharmaceutical Analysis from Central South University and completed post-doctoral work at Fudan University.
Operating as a CXO (Contract Everything Organization), the firm offers a one-stop platform that encompasses research and development, clinical trials, and production technology empowerment for pharmaceutical companies globally. Its services cover the entire lifecycle of a drug, including pharmaceutical research, clinical study services from Phase II to IV, and post-launch research such as quality standard improvements and drug vigilance. The company has a particular focus on the development of classic TCM formulas, innovative TCM drugs, and hospital preparations. As of early 2023, the firm had worked on 83 classic prescriptions, 22 innovative TCM drugs, and successfully registered 56 hospital preparations.
The business model is based on providing specialized outsourced R&D and technical services to pharmaceutical companies and medical institutions, positioning it as a key support enterprise in the TCM industry. In March 2023, the company announced the completion of a Series A financing round of over 100 million yuan, led by the Guangdong Traditional Chinese Medicine Grand Health Fund, with participation from Whige Capital. This funding was intended to enhance its R&D capabilities and construct a smart Chinese medicine research and development base.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2023 | $14M | $55M | Hygeia Capital · Guangdong Traditional Chinese Medicine Health Fund | ↗ |
Growth signals
Latest recorded traffic for Hunan Eneng Biopharmaceutical is 150 monthly website visits, down 51.6% over the last three months. Hunan Eneng Biopharmaceutical's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hunan Eneng Biopharmaceutical in its local ecosystem
The Hunan Eneng Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- HCHygeia Capital
- GFGuangdong Traditional Chinese Medicine Health Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hunan Eneng Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hunan Eneng Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.